ASAH2 and cancer: NC06, an ASAH2 inhibitor, could induce ferroptosis in MDSC by promoting the protein stability of p53 and the expression of Hmox1. Therefore, targeting ASAH2 to trigger ferroptosis in MDSC to enhance the CD8+ T cell activity might facilitate cancer immunotherapy (44).